Michael Koenigsmann

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

Salah‐Eddin Al‐Batran, Nils Homann, Claudia Pauligk et al. · The Lancet · 2019 · 2.6K citations · Full text

Medicine, Oncology, Perioperative Medicine +17

Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial

Salah‐Eddin Al‐Batran, Ralf‐Dieter Hofheinz, Claudia Pauligk et al. · The Lancet Oncology · 2016 · 739 citations

Medicine, Oncology, Pharmacology +16

Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer

Salah‐Eddin Al‐Batran, Nils Homann, Claudia Pauligk et al. · JAMA Oncology · 2017 · 474 citations · Full text

Medicine, Oncology, Surgery +15

Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial.

Salah‐Eddin Al‐Batran, Nils Homann, Harald Schmalenberg et al. · Journal of Clinical Oncology · 2017 · 239 citations

Medicine, Oncology, Perioperative Medicine +15

Lymphocyte subsets' reference ranges in an age- and gender-balanced population of 100 healthy adults—A monocentric German study

Kathleen Jentsch‐Ullrich, Michael Koenigsmann, Martin Mohren et al. · Clinical Immunology · 2005 · 189 citations

Life Sciences, Immunology, Cellular Immunology +12